ClinicalTrials.gg
CompletedNCT05176873Updated Sep 7, 2023

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants

A Phase 1 interventional study of DZD8586 and Placebo in Lymphoma, Non-Hodgkin, sponsored by Dizal (Jiangsu) Pharmaceutical Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-07.

Sponsored by Dizal (Jiangsu) Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2022, 4 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States — 140 open to participants now, 255 under way, 19 of them phase 3. Lymphoma, Non-Hodgkin · United States.

Enrollment
404th of 1,377
64 · median 35
Started
2021
with 53 others
Phase 1
528 of 1,599
47 open now
Registered
1,435th of 1,599
by date

Among the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, this one is the 404th largest by enrollment of the 1,377 interventional ones that give a count, is one of 54 that started in 2021, is one of 528 in phase 1, and was the 1,435th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

140 of the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States are open now. Recruiting first, the newest first:

135 more — sign in →

All 140 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, or all of them as a file.
02

Study summary

This is a study in healthy adult participants. This is the first time this drug has ever been tested in human, and so it will help to understand what type of side effects may occur with this intervention. It will also measure the levels of drug in the body.

Read the detailed description

This is a study in healthy adult participants. This is the first time this drug has ever been tested in human, and so it will help to understand what type of side effects may occur with this intervention. It will also measure the levels of drug in the body.

03

Conditions studied

  • Lymphoma, Non-Hodgkin
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be able to understand the nature of the trial and provide a signed and dated, written form before any study-specific procedures, sampling, and analyses.
  2. Female and/or male aged 18\~55 years (inclusive), at the time of signing the informed consent.
  3. (BMI) 18\~30 kg/m2. Bodyweight of ≥ 45 kg (Female) or ≥ 55 kg (Male).
  4. Non-smoker (never smoked or > 1 year from the last occurrence of smoking).
  5. Participants are healthy as determined by medical history, physical examination, laboratory parameters, vital signs and , performed before the first administration of the study drug, including the following criteria:

    • Normal , ALT, total and serum alkaline phosphatase
    • Normal white blood cell (WBC), and count
    • Normal coagulation function
    • ≥ 90 mL/min or > 80 mL/min/1.73m\^2
    • /QTc interval \< 450 ms
  6. Male participants must be surgically sterile or using an acceptable method of (defined as barrier methods in conjunction with spermicides) during the study (from the time they sign consent) and for 6 months after the last dose of the study drug to prevent pregnancy with a partner. Abstinence is an acceptable form of contraception, provided that the subject agrees to use barrier methods in conjunction with spermicides if they do engage in sexual intercourse.

    However, periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Male participants should refrain from sperm donation throughout this period.

    Female partners (of ) of male participants must also use a highly effective method of contraception throughout this period.

  7. Female participants must have negative pregnancy tests at screening and check-in AND: have been surgically sterile (with documentation of hysterectomy, bilateral oophorectomy, bilateral salpingectomy, bilateral tubal ligation/tubal occlusion) OR (no menstruation for a minimum of 12 months and confirmed by follicle-stimulating hormone (FSH) and serum estradiol at screening) OR, if of child-bearing potential, must be using an acceptable method of contraception such as an intrauterine device, implant or contraceptive injection, or two forms of the following (e.g. diaphragm, cervical cap, oral, patch or vaginal hormonal contraceptive, condom, spermicide, or sponge) for the last three months. All females must agree to continue to use their method of birth control for the duration of the study and a minimum of one complete menstrual cycle.

Exclusion criteria

Exclusion Criteria:

  1. Any condition which in the opinion of the investigator would interfere with the participant's ability to provide , comply with study instructions, confound interpretation of study results, or endanger the participant if he or she takes part in the trial.
  2. Any of the following condition: positive surface antigen (HBsAg), positive antibodies, confirmed positive test result, TB test or COVID-19 test.
  3. History of of any type, except the following: surgically excised non-melanomatous skin cancers more than 5 years before receiving the study drug.
  4. Has donated blood (including blood products) or experienced loss of blood ≥ 500 mL within 2 months before screening.
  5. Reported history or any abnormalities at the screening of cardiac, hepatic, renal, respiratory, GI, endocrine, immunological, dermatological, hematological, neurological, or psychiatrical disease.
  6. Resting blood pressure > 140/90 mmHg at screening (a single repeat measurement is allowed if the initial measurement is outside of these limits). Resting pulse rate \< 45 beats per minute.
  7. Ingestion of grapefruit, grapefruit juice, pomegranate juice, star fruit, or orange marmalade (made with Seville oranges) within 1 week before screening.
  8. Participation in another clinical study with an product administered in the last 28 days.
  9. Have previously completed or withdrawn from this study or any other study investigating DZD8586 and have previously received DZD8586.
  10. Involvement in the planning and/or conduct of the study (applies to both Dizal staff and/or staff at the study site).
  11. Previous enrolment or randomization in the present study.
  12. For women only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding.
  13. Testing positive for alcohol and/or drugs of abuse at screening and check-in.
  14. Self-reported substance abuse (e.g., alcohol, licit or illicit drugs) within 12 months of screening.
  15. Unwilling or unable to limit the substance such as alcohol consumption as defined in the restriction section throughout the course of the study.
  16. Received a live or within 3 months before the first dose of the study drug, except COVID-19 vaccine (within 2 weeks).
  17. Use or intend to use any prescription within 28 days prior to study drug administration, unless deemed acceptable by the investigator (or designee). Concomitant prescription drugs should also be restricted during administration of study drug. Exceptions may be allowed on a case-by-case basis as agreed by the investigator and sponsor's medical monitor if considered not to interfere with the aims of the study.
  18. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations, gastric pH modifiers, and neutralizing antacids within 14 days prior to study drug administration, unless deemed acceptable by the investigator (or designee). Concomitant non-prescription drugs should also be restricted during administration of study drug.
  19. Use or intend to use slow-release medications/products considered to still be active within 14 days prior to check-in, unless deemed acceptable by the investigator (or designee).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Single dose of DZD8586

    Single dose of DZD8586

    Drug: DZD8586

  • Placebo comparator
    Single dose of Placebo

    Single dose of Placebo

    Drug: Placebo

Interventions

  • Single dose of DZD8586. Starting dose of DZD8586 is 20mg. If tolerated, subsequent cohorts will test increasing doses of DZD8586.

  • DrugPlacebo

    A single oral dose of placebo will be given.

06

What researchers measure

Primary outcomes

  1. Number and percentage of participants with adverse event, serious adverse event, clinically defined abnormal vital signs, laboratory values, ECG abnormalities

    Time frame: 6 days after the last dose

Secondary outcomes

  1. Plasma and urine concentrations of DZD8586

    Time frame: 6 days after the last dose

07

Study locations

1 site
  • Frontage Clinical Service 200 Meadowlands Parkway
    Secaucus, New Jersey 07094, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in May 2022, 5 months.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's 5 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2021
First posted
Jan 4, 2022
StartActual
Dec 9, 2021
Primary completionActual
May 11, 2022
CompletionActual
May 22, 2022
Last update
Sep 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05176873
Responsible party
Sponsor
First posted
Jan 4, 2022
Start date
Dec 9, 2021
Primary completion
May 11, 2022
Completion
May 22, 2022
Last update
Sep 7, 2023

Study contacts

Frank Lee
principal investigator · Frontage Clinical Services, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Birelentinib

Start the discussion